Ocumetics Announces Offering of Units

• Financing Announcement: On April 29, 2026, Ocumetics announced a private placement of up to 2,800,000 units at $0.55 per unit, targeting gross proceeds of up to $1,540,000.
• Unit Composition: Each unit includes one common share and one warrant exercisable at $0.75 for three years.
• Use of Proceeds: Funds are designated for first-in-human clinical trials, ongoing R&D, and general working capital.
• Warrant Acceleration: Warrants may accelerate if the stock trades above $1.20 for 30 consecutive days.
• Context: This follows positive six-month clinical results announced on April 20, 2026, which showed improved vision and quality of life for patients in Group One.

• Dilution Risk: The offering price ($0.55) is slightly below the recent market close ($0.58), indicating a discount that will dilute existing shareholders. This is typical for small-cap biotech financing but negatively impacts per-share value in the short term.
• Runway Extension: The capital raises the company's runway to continue clinical trials, which are currently showing positive momentum (6-month results). Without this funding, progress could stall given previous cash burn patterns.
• Debt Management: While this financing improves liquidity, it does not address the $4 million secured convertible debentures maturing in June 2027 (forbearance extended to that date). The company remains dependent on external capital to service debt and operations.
• Clinical Validation: The financing supports a technology platform with validated safety and efficacy data so far, but does not represent a new product breakthrough or regulatory approval milestone itself.
• Market Expectation: Given the history of frequent financings (Nov 2025, Jan 2026, Feb 2026), this announcement is largely expected by the market and priced in, limiting upside surprise potential.

• Company: Ocumetics Technology Corp., a clinical-stage biotechnology company focused on ophthalmic devices.
• Flagship Project: Ocumetics Accommodating Intraocular Lens (IOL).
• Technology: An accommodating IOL designed to fit within the natural lens compartment, allowing dynamic focus shift from distance to near vision without glasses or contacts.
• Development Stage: First-in-Human (FIH) clinical trials completed for Group One; preparing for Group Two surgeries and regulatory submissions.
• Key Milestones Achieved: 1-month, 3-month, and 6-month postoperative results have demonstrated safety and visual acuity improvements (20/40 or better).